ArticleiScience2026
Optimizing plasma-derived small extracellular vesicle purification to enhance downstream applications.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small extracellular vesicles (sEVs) are functional carriers of biomolecules from host cells, making them highly suitable for early disease diagnosis and monitoring disease progression. However, the purification of sEVs from plasma is complicated by the presence of high levels of proteins, particularly lipoproteins. We have developed an original pretreatment method that effectively removes lipoproteins and fibrinogen, thereby facilitating subsequent sEV purification. Sequential application of ultracentrifugation and optical density gradient on pretreated plasma significantly enhances the purity of sEVs, achieving the removal of over 99% of contaminants and increasing mass spectrometry protein detections by 13.3 and 6.3 times compared to traditional ultracentrifugation and size exclusion chromatography methods, respectively. Furthermore, proteomic analysis verified the validity of sEVs isolated using our approach. Overall, our optimized method substantially improves the purity of plasma sEVs without compromising yield, thereby greatly enhancing their potential for clinical testing and basic biochemical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.